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Introduction
By the end of 2016 an estimated 19.5 million of the 36.7 
million people living with HIV globally were accessing 
antiretroviral therapy (ART) (UNAIDS, 2017). Despite the 
enormity of progress in providing access to treatment, 
receiving a positive HIV test result and being encouraged 
to start ART as soon as possible may still present a 
significant challenge.
Access to HIV treatment sustains health, but for someone 
who may not feel ill or question an HIV-positive test result 
“their perceptions of their life-worlds” may not include any 
acknowledgement that they need any form of treatment 
(Takahashi, Wiebe, & Rodriguez, 2001, p. 847). There is a 
fine line between sickness and health: being healthy may be 
an ability to adapt and self-manage (Huber et al., 2011). For 
some people living with HIV who may not have been tested, 
or for those who have been tested but choose not to start 
treatment, this self-management continues while any form 
of ill-health can be contained. Starting ART is an acceptance 
that for adaptation and self-management to continue, the 
time has come for external support (Russell et al., 2016) and 
health can only be sustained by taking treatment.
Wilton (1996) noted in his ethnography among nine 
symptomatic HIV-positive men (from a high-income setting) 
not yet on ART, that the efforts involved in incorporating the 
changing material and perceived parameters of daily life 
with HIV, required a considerable realignment of individuals’ 
“life worlds”. Although encompassing different routines and 
threats, this remains true for those now living with HIV on 
ART, given their perceived fragility of health and the time 
investment required to engage in long-term clinical care to 
maintain their health (Winchester et al., 2017). Much has 
been written about the current manageability of an HIV 
diagnosis. However, reconciling oneself to the altered realities 
of living with HIV, even within the sustained health offered by 
ART, may still take time (Mutabazi-Mwesigire, Seeley, Martin, 
& Katamba, 2014; Russell & Seeley, 2010). Reconciling the 
health-illness tension into self-identity (Takahashi et al., 2001) 
may be compounded by the risk of being identified by others 
as “ill/HIV-positive” if seen to be attending a clinic. This fear 
can be particularly prominent when there is no other health 
explanation that they could plausibly give for their utilisation of 
medical services (Treves-Kagan et al., 2016).
Time and timeliness are pivotal factors in whether the 
current HIV prevention and treatment agendas of “test and 
treat” (immediate treatment on diagnosis) and “treatment 
as prevention” (reduced viral load as a result of taking 
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treatment, thus reducing infectivity) will be successful 
(Dieffenbach & Fauci, 2009; WHO, 2012, 2016). The 
concept of “timeliness” is framed through a biomedical 
lens and operates on the assumption that there is a shared 
understanding between patient and clinician about how time 
is experienced, measured and consumed. It is relatively 
rare to consider a more emic perspective on what might 
constitute an individual’s criteria for when the “right time” to 
initiate treatment is and what might underpin their definition 
of timeliness.
In general, the exploration of time as a critical dimension 
in shaping health-seeking behaviour and the ways in which 
it shapes health has been relatively neglected (Strazdins 
et al., 2011). Notable exceptions to this are the body of 
chronic illness research which has focused on time as a 
resource for accessing care and the competing priorities 
and commitments which impede the time a person may 
have to seek treatment (Dempsey, Dracup, & Moser, 1995; 
Schoenberg, Peters, & Drew, 2003). Although increasing 
attention is paid to refusals (Katz & Bangsberg, 2016; Katz 
et al., 2015) and “lateness” in relation to ART (see, e.g., 
Kigozi et al., 2009; Mocroft et al., 2013; Moreno, Mocroft, 
& d’Arminio Monforte, 2010; Mukolo, Villegas, Aliyu, & 
Wallston, 2013; Parrott et al., 2011), given the role time plays 
in the successful execution of the broad HIV prevention and 
treatment agenda, understanding what “late” might mean for 
an individual has not received so much attention. Clinically 
there is variation in how quickly some individuals need to 
get on to ART having been infected, with some people with 
an infection that progresses slowly effectively having “more 
time” to initiate treatment. However, the clinical messaging, 
which now focuses on getting everyone on to ART as soon 
as possible, cannot necessarily engage with the nuances 
of this variation. It is important to pay attention to the 
divergence between this global clinical policy and how the 
urgency and necessity of starting treatment is interpreted by 
those that this policy aims to reach. 
An irony of the success of ART is that it can render HIV, 
and thus its own necessity, invisible. What is still visible are 
some of the physical scarring and side effects associated 
with earlier ART options. The effects of lipodystrophy (the 
redistribution of body fat) caused by some earlier drug 
regimens (Staszewski et al., 1999) may continue to embody 
to some within the community the risky consequences, 
both physical and social, of being treated for HIV (Katz et 
al., 2015).
Therefore the concealment of the daily success of ART 
treatment for those who initiated treatment before becoming 
symptomatic may mean that there is a time lag between 
the newer realities of life on ART and the outdated but 
still prevailing social norms about the compromised health 
and social status of those on ART. Seen through this lens, 
rather than that of the clinical evidence, if their untreated 
HIV remains personally manageable, the incentives for early 
treatment to maintain relative health may be less compelling. 
An ambiguity may still exist for them in whether immediate 
ART is the route to healthiness (Curran et al., 2014). 
With the advent of test and treat, a person “delays” 
treatment if they do not start ART soon after their HIV-positive 
diagnosis being confirmed. There has been a rapid change in 
policy about the “right time” to initiate HIV treatment (Insight 
Start Study Group, 2015), and the subsequent incentives 
for “timely” presentation for diagnosis and treatment. Is 
this information being incorporated into the decisions and 
actions about treatment and provoking a recalibration of 
an individual’s expectations of what their life might be like 
living with HIV through being on ART (Russell et al., 2016; 
Sprangers & Schwartz, 1999)? In this paper, we examine the 
logic that individuals who presented very late for treatment 
(CD4 < 100 cells/mm3) use to account for the time they took 
to go for an HIV test and/or to initiate HIV treatment.
The REALITY trial (Reduction of EArly mortaLITY in 
HIV-infected adults and children starting antiretroviral 
therapy) was conducted in nine centres in four countries 
(Kenya, Malawi, Uganda and Zimbabwe). This was a 
randomised controlled trial with the primary objective of 
identifying effective, safe and acceptable interventions to 
reduce early mortality in HIV-positive adults, adolescents, 
and older children (5 years or more) ART with CD4 < 
100 cells/mm3. Three methods were used to reduce early 
mortality following ART initiation: (i) increasing the potency 
of ART with a 12-week induction period; (ii) augmented 
prophylaxis against opportunistic/bacterial infections and 
helminths for 12 weeks; and (iii) ready-to-use supplementary 
food for 12 weeks. Each intervention was compared with 
standard of care (Hakim et al., 2017).
In response to addressing the trial research question 
about reducing early mortality among those initiating ART, 
a qualitative sub-study was undertaken to find out the 
reasons why participants presented late for HIV treatment. 
This sub-study was conducted at two sites in Uganda: Gulu 
(northern Uganda) and Mbarara (south-western Uganda), 
and the site in Harare, Zimbabwe.
Methods
Study population and sampling
Forty-eight participants enrolled in the REALITY trial 
participated in the qualitative sub-study in 2015. Males 
and females aged 10 years and above were recruited, 24 
from Uganda and 24 from Zimbabwe. Purposive sampling 
was used to include participants randomised from the two 
extreme arms in the trial. Half were on the intervention arm 
which combined all three interventions being investigated, 
namely participants receiving both enhanced ART and 
anti-infection treatment plus ready to use food supplements 
for 12 weeks. The other half received none of the 
interventions where participants received standard of care 
in each country. The qualitative sample was designed to be 
as representative as possible of the various age groups and 
gender of the trial population.
The REALITY social science study was conducted 
in research settings in Mbarara and Gulu, two of the four 
REALITY trial sites in Uganda. The Mbarara site is located 
within a research facility in the regional referral hospital 
where there is a department which handles HIV testing and 
treatment which receives many patients from within Mbarara 
and neighbouring districts. The Gulu site was based in a 
specialist research clinic which provides for patients from 
Gulu and neighbouring districts. 
In Zimbabwe, the REALITY trial site was in Harare in a centre 
set up for clinical research situated within a referral hospital. 
Participants came from Harare and the surrounding areas.
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Data collection and analysis
Two interviews were conducted with each participant. 
Phase 1 interviews were conducted after the participants 
had been in the trial for 4 weeks to learn how they were 
living before ART and how they came to join the REALITY 
trial. Phase 2 interviews were conducted after the 12-week 
intervention had concluded to find out about the adjustment 
processes that followed being initiated on ART.
Topics that were discussed included adherence, 
disclosure and social support systems that were available 
to the participants once they started HIV treatment. 
Participants were asked about their illness history and 
what prompted them to take an HIV test, to understand 
what factors may have influenced the decision to test for 
HIV and what steps they took after the HIV test to seek 
treatment and care. Although all trial participants were 
initiated on to ART when they were enrolled into the trial, 
some participants who tested positive at the start of the trial 
may have received a positive test result at an earlier point, 
but not initiated treatment. Those participants who had had 
prior confirmation of their HIV-positive status were asked 
why they had not sought treatment soon after receiving a 
positive test result.
All the interviews were audio recorded, transcribed 
verbatim and translated from local languages into English. 
A grounded analytic approach to thematic analysis was 
adopted, using systematic case comparison, including 
across study sites and key sampling dimensions such as 
gender and age, and negative case analysis throughout 
(Strauss & Corbin, 1994). Core themes which emerged 
through our first level (participant description) and second 
level (concept-driven categories) coding were: good 
enough health; consumption of time; curtailed choices; and 
community discourses about anti-retroviral treatment. 
Findings 
Table 1 shows details of participants by age and sex as 
well as WHO stage at presentation (see supplementary 
material for Table S1 which includes viral load and CD4 
count data). We used WHO stage in Table 1 because how 
ill someone felt was a very important factor in whether a 
person presented for testing. Those presenting with Stage 4 
symptoms were often very ill indeed.
“Late” presentation
By definition, all participants in the trial had low CD4 cell 
counts (<100 cells/mm3), but a substantial number were very 
low (<50 or even <10 cells/mm3). Viral loads were also very 
high (Table 2). However, these laboratory test results were 
not known to participants. In contrast, several participants 
presented for HIV testing with many symptoms. The 
deterioration of their health tended to have been gradual, 
which meant that they were able to ignore or minimise the 
significance of their worsening condition. Accounting for why 
they presented late for HIV testing, many stated that they 
thought that their illness was just “ordinary” and/or “minor” 
ailment which would resolve by itself or with self-medication. 
I would mainly feel weak and buy tablets to gain 
energy and sometimes I would fail to eat food (no 
appetite). I was a very fat woman weighing 90kgs 
but then I noticed I was losing weight and all my 
clothes would fall off so I always wondered what 
might be the problem…just losing weight, itching all 
over and I would just think that maybe it is an illness 
probably Candida so I would buy tablets and insert 
there (vagina). I was suspecting diseases such as 
syphilis and not HIV (female, 50 years, Uganda).
An intrinsic thread within many participants’ accounts was 
an expectation that it was not uncommon for their health to 
be compromised to varying extents at different points. Some 
adverse physical symptoms were to be anticipated and if 
they were manageable then this did not disrupt their sense 
of “healthiness”. Health was thus defined as an absence of 
a debilitating physical condition, rather than as a fulfilment 
of an ideal physical state. Two men, both WHO stage 3, 
demonstrated this when they said:
It never came into my mind [that it was HIV-related] 
[…] it’s common for one to get sick here and there 
then you get well and get back to your daily life, you 
start doing what you were doing or just doing your 
work (male, 43 years, Zimbabwe)
So, these are the kind of things [illness] you expect 
as a living being. Trees do lose their leaves at some 
point and so you may think that it is just something 
people experience and it will what? It will come 
to pass. That is the “belief” I had, that it’s nothing 
serious and that it is a phase which will eventually go 
away on its own (male, 42 years, Zimbabwe).
In the face of evident ill-health and in a society where 
there is a relatively high risk of acquiring HIV, many 
participants reported their health problems at that time to be 
manageable. For as long as it was feasible, they had treated 
the presenting symptoms at general clinics or using herbal 
treatment. For example, a 38-year-old man in Uganda (WHO 
stage 4), said:
I used to be sick and would feel so weak but was 
using herbal medicine. I had a skin rash and lots 
of blisters so I would self-medicate…knowing that 
it was syphilis, I went to the hospital and they also 
tested it and treated syphilis.
A 36-year-old man (WHO Stage 1), also from Uganda, 
commented:
I would get treatment for malaria and cough but they 
wouldn’t cure fast; they get cured for one month 
and recur again. I was buying it (treatment) in small 
towns where there are clinics with drugs. But I 
noticed that my energy was becoming low. 
Not late, instead not yet necessary
Before getting to the point of testing and getting treatment, 
most of the participants reported being aware of their 
own risk of becoming or already being HIV-positive. 
Consequently, the focus on alternative causes and 
treatment courses was often in contradiction with the 
information that they had about their own likelihood of having 
become HIV-positive. The probability of being HIV-positive 
themselves was usually grounded in knowing that their 
partner had previously been diagnosed as HIV-positive. 
Some participants in relationships were aware of their 
sexual partner’s HIV-positive status, however, they were 
reluctant to acknowledge that they may also be HIV-positive. 
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This was particularly common among men. They described 
not being ready to consider themselves ill and to accept and 
reconcile themselves to having an altered status of liminal 
health. For men in the study, for whom the act of testing 
and then being labelled (or self-identifying) as HIV-positive, 
this seemed to constitute an affront to their embodiment of 
masculinity through their consequent compromised strength 
and health. This reticence to realign their understanding of 
their perceived healthiness further delayed the act of testing 
or accepting the need to start treatment. 
She [his wife] would tell me to go and take a test but 
I would tell her that I have not yet reached that time, 
deep down I feared (male, 40 years, Uganda, WHO 
stage 1).
My wife forced me…you go [laughs]. I would be 
in doubt but she told me to go [and test] because 
she tested and found that she is infected (male, 50 
years, Uganda, WHO stage 1).
Table 1: Study participant country, age, sex, marital status, HIV status before REALITY and WHO disease stage on first visit to study clinic
Country Age (years) Sex
Marital  
status
Aware of HIV status 3 months 
before REALITY trial
WHO 
stage*
Uganda 39 F Single Yes 1
Uganda 30 M Single Yes 1
Uganda 32 F Single Yes 1
Uganda 38 F Married No 1
Zimbabwe 31 M Married No 1
Uganda 36 F Married Yes 1
Uganda 36 M Married No 1
Uganda 38 F Single Yes 1
Uganda 50 M Married Yes 1
Uganda 40 M Married No 1
Zimbabwe 40 M Married No 1
Uganda 24 F Married Yes 1
Uganda 47 M Single No 1
Uganda 30 F Single Yes 1
Uganda 50 F Single Yes 1
Zimbabwe 12 M  Single Yes 2
Zimbabwe 46 M Married Yes 2
Uganda 30 M Single Yes 2
Uganda 32 F Single No 2
Zimbabwe 17 M Single No 2
Zimbabwe 33 F Single No 2
Uganda 30 F Single Yes 2
Zimbabwe 38 F Divorced Yes 2
Uganda 26 M Married Yes 2
Zimbabwe 29 M Single No 2
Zimbabwe 53 F Divorced Yes 3
Zimbabwe 42 M Married No 3
Zimbabwe 33 M Widowed Yes 3
Zimbabwe 12 F Single Yes 3
Zimbabwe 40 M Married Yes 3
Zimbabwe 57 F Married Yes 3
Uganda 39 M Married Yes 3
Zimbabwe 32 F Divorced Yes 3
Uganda 63 M Married Yes 3
Zimbabwe 35 F Widowed No 3
Zimbabwe 44 M Divorced No 3
Zimbabwe 29 M Married Yes 3
Zimbabwe 43 M Divorced No 3
Uganda 52 M Married Yes 3
Zimbabwe 53 F Widowed No 3
Zimbabwe 46 F Married No 4
Zimbabwe 51 M Married No 4
Zimbabwe 47 F Divorced Yes 4
Uganda 38 M Single No 4
Uganda 28 M Single No 4
Zimbabwe 32 F Divorced Yes 4
Uganda 23 F Single Yes 4
Uganda 19 M Single No 4
 *See http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf for an explanation of the staging
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A 46-year-old woman from Zimbabwe talked about how 
her husband was resisting testing after she disclosed her 
status and that she was already initiated on ART:
I came back from the hospital and told my husband 
and showed him my hospital cards and he just said 
okay. I told him that he also must be tested because 
that is what they told me at the clinic and he just said 
I am not sick. Each time I go for my review they ask 
me if he was tested and I keep on saying no and 
they keep on asking saying he must be tested.
The men explained that the delay in confirming their own 
positive HIV status through testing and in initiating treatment 
was because they had “more time” before it became 
necessary to start ART. Treatment was not yet necessary 
because they considered that they were relatively successful 
in managing their symptoms, which enabled them to define 
the source of any ill-health as being something, anything, 
other than HIV. If they were still able to maintain a healthy 
enough body to work and get by, it was not yet necessary to 
contemplate a different course of action. 
However, once they were no longer able to work, the 
logic of denial ceased to be productive. As such, health, or 
at least “good enough” health, was defined by having more 
time. They were still healthy enough to justify living with 
ambiguity about their HIV status even if they had symptoms. 
The circumstances surrounding the decision to finally 
have an HIV test differed among participants. For some 
participants, once they noticed their symptoms were 
persistent and no longer manageable, they made a personal 
choice to go for HIV testing. A 43-year-old man from 
Zimbabwe (WHO stage 3), is an example:
But when I realised that I was not getting better I said 
to myself let me go and have my blood checked. The 
first day I went but did not get in [HIV testing rooms] 
and I came back but then I regretted and that night 
it got worse I could not sleep and I said I am going 
back tomorrow so I gained the courage and that’s 
when I got tested. 
However, the decision to test was commonly framed as 
stemming from realising they no longer had the option to 
pursue any other course of action. Participants described their 
circumstances or the unavoidable gravity of their ill health as an 
irresistible pressure. Their options and “time” were running out:
I was forced because I noticed that my health was 
becoming worse each day. The size I was at was 
reducing. I first got an illness that lasted sometime; 
the stomach would pain me so much but I refused to 
go to the hospital and instead used herbal treatment 
and I drank so much but the stomach refused [to get 
better] (male, 40 years, Uganda, WHO stage 1).
Some participants developed what would otherwise be 
very serious illnesses such as meningitis and psychiatric 
problems but did not relate these illnesses to HIV. In these 
cases, it was health workers who advised such participants 
to take an HIV test. For example, a 19-year-old man from 
Uganda (WHO stage 4) was brought by his mother to 
the hospital. He was later tested and was found to be 
HIV-positive. He said:
The head was paining very much and they removed 
some water [fluids] from the back [spine] and that 
is when the pain subsided. They diagnosed it as 
meningitis and started treatment. I spent two months 
on the ward and later a doctor took off my blood and 
they tested it and I was found to be HIV-positive.
A 38-year-old man from Uganda (WHO stage 4) had 
a similar experience after complaining of a headache and 
developing complications:
But the problem was severe headache, so I was put 
on drip, I spent the night there as they put me on the 
drug. Then in the morning they examined my back 
and took off some water [fluids] from the spine and 
tested it and they told me that I had meningitis. 
A sub-group of participants who had already tested at an 
earlier point (months or sometimes years before) but had 
not taken up the opportunity for treatment did so when they 
joined this trial. There were instances where the delays 
between testing and treatment were attributed to a lack of 
available treatment options, delays in laboratory monitoring 
or the return of CD4 test results or patients failing to pursue 
a referral. However, for all of those who had previously 
received a positive test result, none had considered that 
initiating treatment was urgent. So, a similar logic applied, 
even among those who had tested: until they fell ill to the 
extent that it was unmanageable, they had more time. 
Having encountered problems accessing CD4 tests, many 
participants waited until they fell sick before returning to seek 
any further care. In some cases, this meant considerable 
time had elapsed between receiving a positive test result 
and having a CD4 test done and then starting ART. 
There were some exceptions to this where individuals had 
initially received a positive test result and had a CD4 result 
which was, at that time, above the threshold for initiating 
ART. However, the pattern was that individuals were waiting 
until they became sick to re-engage with care. Clinically 
they were then classified as “late presenters”. A 53-year-old 
woman from Zimbabwe (WHO stage 3) said: 
This year [2015] I fell sick and went to the clinic and 
they took a CD4 count. My results delayed coming 
out and I was told to come a week after, I went back 
after one week and I was told to come after two 
weeks. Then I was told I should come on a Monday 
and then on a Friday but I never got the results and I 
was getting frustrated then one nurse advised me to 
go to a different clinic. I then went with my husband 
and got tested and found that my CD4 count was 55 
on the same day.
It’s “about time”: listening to others
In all cases seeking testing or treatment was constructed 
as prescient and unavoidable. Although in some cases, 
as shown above, it was described as a personal decision 
to seek a test and/or to initiate treatment, in many cases 
this “individual” decision to pursue this course of action 
was shaped by partners, relatives, neighbours and friends 
who convinced them that it was “now time” to act. The 
dwindling capacity of individuals to successfully manage the 
symptoms without ART meant that it became time to listen 
and accept the advice of others to act. The opportunity for 
maintaining health tended to have already passed, what 
would be clinically defined as “late”, as this group of people 
were all symptomatic when presenting for testing. There was 
a gendered pattern to this.
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Most of the women in our study described getting tested 
and agreeing to initiate ART of their own accord or through 
receiving standardised health care for another condition, 
such as through antenatal care when pregnant. Only a few 
women reported going for testing after others insisted they 
do so:
I first got a miscarriage and was badly off. So I got 
some medicines from a clinic but that didn’t help. 
Then my mother came and said you should go to a 
hospital and they test you. That is because I didn’t 
have energy and had told her the problem that I 
got [miscarriage]. So I went to a testing centre and 
they tested me for HIV and found that I had it. [My 
mother] noticed that I didn’t have energy. For me I 
thought it was due to the miscarriage but also my 
husband died and he had HIV that is why my mother 
told me that you have to go [and be tested] (female, 
30 years, Uganda, WHO stage 2).
Across our study there was a pattern that men reported 
tending to only acknowledge the necessity of testing once 
they had become debilitated by ill health and were no longer 
effectively able to function or had been repeatedly urged to 
test by family members. For some, in the face of failure to 
treat their condition any other way, ART became necessary 
to restore their health:
But for me to come here, I had very serious 
headache, throbbing so much and I wasn’t able, so 
the neighbours came and removed me from down 
where I was and they brought me to hospital. My 
eyes became blind and I was really going to die. 
They took me to some clinic and had me tested and 
I had HIV (male, 38 years, Uganda, WHO stage 4).
Within our study, it was reported that couple-based testing 
was initiated by women. This was often only done after 
considerable resistance from the male partner and once 
other critical conditions were met, namely debilitated health 
as described above. 
My wife told me that I was losing weight and that I 
should be tested for HIV but I was not convinced 
as I didn’t realise it then that I was losing weight. I 
could still do my work. I don’t know what my wife had 
observed because she kept saying you need to go 
and see a doctor but I was not sick at the time. After 
sometime, that’s when I realised I was becoming 
weak and I started coughing. When I got worse that 
is when I went to the clinic with my wife and we were 
tested together for the first time (male, 31 years, 
Zimbabwe, WHO stage 1).
Present when they are symptomatic and they have run 
out of “time”: when it is time to
A key factor in the delay in seeking treatment was the fear 
which existed around both the consequences of testing and 
of treatment. Although ART had been available for many 
years, the immediacy of being able to start treatment did not 
necessarily allay the significance involved in the recalibration 
of self-identity and risks to the self in doing so. A 47-year-old 
woman from Zimbabwe (WHO stage 4) is one example:
It is difficult to accept that status [HIV-positive] 
even though you will be looking back at your past 
behaviour and you might be suspecting it but you 
just don’t want that confirmation to say you have 
HIV. I once suspected it, there was a time about two 
years back when I got sick but was quick to dismiss 
it saying I have been bewitched. So, the issue of 
acceptance is what causes people to say ha it’s not 
HIV but just chest pains, you will just be suspicious 
but one can just say I was bewitched because we 
Africans believe in being bewitched.
Following this logic, testing is scary because it confirms 
an HIV-positive status. However, initiating treatment is also 
frightening because of the perceived related risks of being 
identified as HIV-positive through attending the clinic and 
being seen taking the pills. It was described as burdensome 
in terms of time, but also in the unwelcome reliance on 
indefinite treatment in which their health would always 
subsequently be mediated by medication. 
An additional factor was participants’ concerns about the 
side effects that come with taking drugs. Many participants 
spoke about the negative stories which circulated about 
the effects of ART within the community. The response to 
these narratives though was varied. Some described that 
their fears of encountering difficulties with the treatment and 
causing resistance acted as a motivation to adhere well to 
their treatment. However, others described it as having put 
them off wanting to start ART at all. It was the possibility of 
ill health that convinced them of the necessity of treatment 
despite their fears, not because they had been persuaded of 
the treatment’s tolerability. 
What I mostly feared was in the first place when they 
talked about these drugs that we take they would 
speak very harsh and scary words. Like, can you 
take ARVs [antiretrovirals]; that tablet cannot go 
past the throat and even if it goes past, it is going to 
affect you and you will get transformed and become 
a nuisance, you will even grow a bump on the back 
(male 40 years, Uganda, WHO stage 1).
The dilemmas that these frightening narratives provoked, 
which may not be widely discussed or acknowledged within 
the clinical community, were described by a 40-year-old man 
from Zimbabwe (WHO stage 3): 
I hesitated to go on treatment after they [clinic staff] 
told me about the pills because people were saying 
the pills will make you mad you will not even sleep. 
Some people were saying you can dream about 
pigs and you will be shouting pigs, pigs pointing at 
them saying ‘see those pigs’ (laughs). But these 
issues are bad because they cause people to lose 
hope with the programme. People will be afraid of 
the programme [HIV treatment and care] because of 
what goes around in our communities. Even when 
I came here and I was given the pills I didn’t want 
to take them but my wife was the one who insisted 
saying, ‘you must not listen to what people say. 
What you want is to get better’. Plus the pain from 
the piles was troubling me, I then gained courage 
and said I want the piles to go away.
Discussion 
The biomedical logic within the era of test and treat is that 
HIV-related illnesses are essentially avoidable. Test and 
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treat is all about maximising the opportunity to retain health 
for the HIV-positive individual who presents before they 
become severely sick and before their immune system is 
too damaged. Connected to this, onward transmission is 
also considered theoretically preventable as by being on 
treatment an individual can have an undetectable load and, 
if that is maintained, cannot infect others (Rodger et al., 
2016). Within our sample, several people had substantial 
HIV-associated symptoms and a number had very high viral 
loads (Table 2), although these were not necessarily the 
same people.
However, our findings illustrate that the logic of the lived 
experience of those participating in our study is at odds 
with the biomedical logic of test and treat. We found that 
individuals do not consider themselves as presenting late (or 
at least they do not before starting treatment); instead they 
present when it is absolutely necessary. The need to begin 
treatment is not yet urgent if they think they have more time. 
There was a disparity between the clinical guidelines and the 
lay interpretations of our participants in what constitutes the 
criteria for it to be necessary to start treatment. This relates 
to a significant divergence in how time is conceptualised as 
a resource for healthiness: how much time can be consumed 
once HIV-positive and still be considered “healthy” without 
treatment. In our participants’ views the duration is more 
elastic and plentiful than indicated within the current clinical 
guidelines. In addition, the changes in clinical messaging 
can take time to filter through to patients and the wider 
community. This is compounded by the relatively rapid 
clinical progress (and resultant changes to thresholds for 
starting treatment). 
This study was conducted in 2014–2015 during the very 
early stages in the shift towards the policy of test and treat in 
both Uganda and Zimbabwe (test and treat was available for 
some key populations in 2014, but for the general population 
the implementation of the policy change was in 2016). We 
acknowledge that individuals may receive faster referrals 
for testing and then may be more proactively encouraged to 
rapidly initiate ART had we conducted a similar study today. 
As such, our study cannot act as an evaluation of the impact 
of the test and treat policy on potential late presenters. 
However, the contribution our study makes is in identifying 
important features of participants’ experiences of time in 
relation to their own health, as well as their expectations 
of what it entails to accept that they need to start ART. 
These in turn offer productive explanations for why people 
may present late. They are pertinent in informing how the 
message of the test and treat policy should be crafted 
to emphasise the advantages of starting ART as early as 
possible for an individual to maintain their health and protect 
others in order to encourage earlier presentation amongst 
more people and thus optimise its success. 
Importantly we found that participants’ perceived sense of 
health may not be intrinsically disrupted by an individual’s 
implicit assumption that they have probably acquired 
HIV. The disruption appears to be embedded within the 
confirmation of an HIV-positive status and the push to initiate 
treatment. We argue that the time-lag that we have noted 
between participants appreciating their own likely positive 
status and acting on it tells us three things. First, that many 
of our participants do not necessarily expect or anticipate 
perfect health, but instead they need sufficient health to 
continue to function and in most cases. This means still 
being able to work or be “productive” in some form. Second, 
and intrinsic to this, is appreciating that many people delay 
acting because they are not yet ready to accept their 
recalibrated identity (Russell et al., 2016). Starting treatment 
might improve their health, but initially at least it involves 
confronting a new identity which explicitly involves a liminal 
state of health. Third, there is a tenacious concern as to 
what the impact of the treatment will be on their “life worlds” 
and so people postpone engaging with HIV care until they 
need to do so and this is done to restore, rather than protect 
or maintain, their health. 
The definition of “good enough health” for our 
participants was having time to act later. Having more or 
enough time was used to justify “delaying” mostly because 
they felt healthy and therefore could postpone testing and 
treatment. This has often been given as one of the reasons 
by people who present late (Rangarajan et al., 2014; 
Siedner et al., 2015).
Considering the time it will take to allow people to 
reconcile themselves to their new confirmed reality that they 
are HIV-positive before initiating treatment has received 
relatively little attention within the shift towards test and treat 
(Mbonye et al., 2016). For some of the participants, their 
hesitancy related to feeling that they needed time to think 
about the consequences of being HIV-positive and starting 
treatment. The message of ART as a route to maintain a 
form of “complete” health (i.e., the absence of initial or 
ongoing HIV-related illnesses) rather than an opportunity 
to restore health (Takarinda et al., 2015), has not yet 
percolated throughout communities in high-prevalence 
settings.
In this study, there were no differences by gender in the 
state of health participants were in when they enrolled in the 
trial (nor were there differences across the three sites). All 
were enrolling late, given the focus of the study, and both 
men and women presented when they were ill with many 
HIV-related symptoms. In addition, many of them had taken 
HIV tests and therefore knew they were HIV-positive for 
some time before being enrolled into the REALITY study. 
This means that they were aware of their risk but had not 
sought treatment at this point. This can be attributed to 
treatment access because we note that from the narratives 
of these participants that an inability to immediately 
start on treatment contributed to their ill health, a finding 
corroborated another study (McGrath, Kaawa-Mafigiri, 
Bridges, & Kakande, 2012).
However, we found that women were more likely than men 
to endure severe symptoms for shorter periods and started 
treatment on their own initiative or because of antenatal 
care. Women also mentioned being encouraged by their 
friends or family to go and test once they had persistent and 
severe symptoms. So, while they presented late in clinical 
terms they appeared to act more quickly than men when 
symptoms became severe. 
Men often put off seeking care until they were left with 
little choice but to go and test for HIV, many times at the 
insistence of their partners. Some men presented with 
very severe illness because they had taken much longer 
to make the decision to test and seek for care, perhaps 
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because of the fear of the diagnosis and the belief they 
were strong enough to manage their ill health (Siu, Seeley, 
& Wight, 2013).
Therefore, challenges in reconciling a healthy body with 
lifelong treatment for an illness may be particularly gendered, 
as has been shown elsewhere (Parrott et al., 2011; Skovdal, 
Campbell, Nyamukapa, & Gregson, 2011). The messaging 
needs to be targeted, particularly towards men, including 
through workplace outreach, to confront the attitude that 
ART becomes a tolerable option only once they have 
become so ill that it substantially impedes their capacity to 
function and work. Testing and treatment outreach services 
need to engage with local conceptualisations of masculinity 
which emphasise the attainment of health through ongoing 
productivity, even if that is supported by ongoing clinical 
treatment (Siu et al., 2013). 
Our findings also emphasise the outdated but pernicious 
concerns which circulate around the side effects of ART 
(Renju et al., 2017). Although many of these are now 
inaccurate, most of what the participants were referring 
to relates to the historical roots of earlier treatment where 
side effects such as lipodystrophy were more common. 
Most treatments have now become much more tolerable, 
the physical signs that someone is on treatment and that 
ART is working are so “undetectable” that for some people, 
including many of those in our study who presented late, 
the community narratives about the harsh, risky effects of 
treatment are not changing because they do not “see” those 
on the more recent, effective, invisible treatments. The 
perverse effects of the success of more recent ART is that 
those on ART are invisible and so the early examples of 
ART side effects remain the reference point through which 
some people assess the risks in starting on treatment. 
Failure to counteract and address these community 
narratives about the side effects of ART is likely to affect 
uptake of HIV testing and retention on treatment (Wringe, 
Renju, Seeley, Moshabela, & Skovdal, 2017). Again, the 
messaging around test and treat needs to place greater 
emphasis on the relative tolerability of ART, the protective 
opportunities of treatment as prevention and the comparative 
absence of side effects since the early days of HIV treatment 
availability in these settings. An essential component in 
incentivising early or timely initiation of ART is to emphasise 
the increased likelihood of not having physical markers of 
HIV and rendering HIV invisible if treatment is started as 
soon as possible.
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